Mrsa Related Complicated Skin Infections Therapeutics
1. Vibativ patent expiration
Treatment: Method for treating bacterial infection; Method of treating a staphylococcal infection; Method of treating bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7531623 | CUMBERLAND | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7544364 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(4 years ago) | |
| US6872701 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Jun, 2021
(4 years ago) | |
| US8158580 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(4 years ago) | |
| US6635618 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Sep, 2023
(2 years ago) | |
| US7008923 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US7700550 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US7208471 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US8101575 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US6858584 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(3 years ago) | |
| US7351691 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 11, 2014 |
| New Indication(I-673) | Jun 21, 2016 |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 11 September, 2013
Market Authorisation Date: 11 September, 2009
Dosage: POWDER
More Information on Dosage
VIBATIV family patents
